Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice.

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck surged 3.35%, indicating a bullish trend as it challenged the $83.00 resistance mark. The stock's ascent is backed by ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.

REPORTS SHARE STAKE OF 39,400 SHARES IN DISNEY- SEC FILING * REPORTS SHARE STAKE OF 44,600 SHARES IN MERCK * DISSOLVES SHARE ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...

Merck & Co.’s COVID-19 pill was cleared by U.S. regulators Thursday, giving high-risk American patients a second at-home treatment just as the omicron variant is causing cases to surge around ...

Rival antiviral pills from Pfizer Inc. and Merck & Co. that demonstrated efficacy in trials of adults with COVID-19 who are at high risk of serious illness are now both in use.